55204-14-3

Upstream product

• 79-46-9 2-nitropropane 
• 74733-27-0 methyl 4-bromomethyl-2-methoxybenzoate 
• 201230-82-2 carbon monoxide 
• 139102-34-4 methyl 4-bromo-2-methoxybenzoate 
• 72135-36-5 4-bromo-2-methoxybenzoic acid 
• 50-85-1 2-hydroxy-p-toluic acid 
• 121-33-5 vanillin 
• 67-56-1 methanol 
• 194018-68-3 vanillin triflate 
• 189094-76-6 methyl 4-[(acetyloxy)methyl]-2-methoxybenzoate 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 57757-74-1 3-Methoxy-4-(methoxycarbonyl)benzyl Alcohol 
• 186697-31-4 methyl 4-(dibromomethyl)-2-methoxybenzoate 
• 704-45-0 2-methoxy-4-methylbenzoic acid 

Downstream Products

• 42137-51-9 4-formyl-2-hydroxy-benzoic acid methyl ester 
• 1351169-33-9 C₂₆H₃₂O₄ 
• 1351169-42-0 methyl 2-(3-{2-[2-(2-{2-[(S)-2-((2S,3R)-3-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-2-hydroxy-4-phenylbutanamido)-4-methylpentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-27-1 2-[3-(2-{2-[2-(2-{(S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanamido}ethoxy)ethoxy]ethoxy}acetamido)propoxy]-4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid 
• 1351169-43-1 (S,E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoate 
• 1351169-28-2 (S,E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoic acid 
• 1351169-34-0 C₂₅H₃₁BrO₄ 
• 1351169-35-1 (E)-methyl 4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-hydroxybenzoate 
• 1351169-36-2 (E)-methyl 2-[3-(tert-butoxycarbonylamino)propoxy]-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]benzoate 
• 1351169-37-3 (E)-methyl 2-(3-aminopropoxy)-4-[3-(3,5-di-tertbutylphenyl)-3-oxoprop-1-enyl]benzoate hydrochloride 
• 1356059-97-6 2-hydroxy-4-(2-oxo-5,6-diphenyl-1,2,3,4-tetrahydropyridin-4-yl)benzoic acid 
• 1356060-17-7 2-hydroxy-4-(2-oxo-6-phenyl-5-(thiophen-3-yl)-1,2,3,4-tetrahydropyridin-4-yl)benzoic acid 
• 1356059-98-7 2-hydroxy-4-(6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-5-(thiophen-3-yl)-1,2,3,4-tetrahydropyridin-4-yl)benzoic acid 

Relevant academic research and scientific papers

Compounds with neuroprotective effect, and preparation method and application thereof

The invention relates to compounds with a neuroprotective effect, and a preparation method and application thereof. Specifically, the compounds disclosed by the invention have a structure as shown in a formula I, and the definitions of all groups and subs

Novel compounds that are inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma

These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES

A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

HISTONE DEMETHYLASE INHIBITORS

This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators

NMDA receptors are tetrameric complexes composed of GluN1 and GluN2A-D subunits that mediate a slow Ca2+-permeable component of excitatory synaptic transmission. NMDA receptors have been implicated in a wide range of neurological diseases and thus represent an important therapeutic target. We herein describe a novel series of pyrrolidinones that selectively potentiate only NMDA receptors that contain the GluN2C subunit. The most active analogues tested were over 100-fold selective for recombinant GluN2C-containing receptors over GluN2A/B/D-containing NMDA receptors as well as AMPA and kainate receptors. This series represents the first class of allosteric potentiators that are selective for diheteromeric GluN2C-containing NMDA receptors.

NMDA RECEPTOR MODULATORS AND USES RELATED THERETO

This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS

The present invention is directed to novel dihydropyridin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors and/or Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same.